Description

Bayer Aktiengesellschaft: Initiation of Coverage- How the Pharma Giant Plans to Outrun Xarelto’s Patent Cliff!

Bayer AG has reported its first quarter results for 2025, revealing a mixed performance across its business divisions amidst challenging geopolitical and economic conditions. The company’s overall sales remained flat year-over-year, in line with its guidance range of -3% to +1%. In the Crop Science division, sales declined by 3%, primarily due to regulatory impacts affecting high-margin sales, leading to a lower EBITDA margin compared to the previous year. Nonetheless, Bayer anticipates growth in this sector during the second quarter and remains focused on improving midterm performance, having announced changes to its production and R&D network in Germany.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!